ANNA-BIOSCIENCES
22.6.2021 15:02:10 CEST | Business Wire | Press release
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.
The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.
Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.
With today’s announcement, Anna Biosciences underscores both its initial successes in the lab and the successful patenting of the Syntem Platform. The company is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.
The Syntem Platform also shows strong promise for use against cancer and other pathogens. Research into the application of Syntem for oncological targets is currently underway. The resulting therapies could offer precision targeting, and the potential to mitigate side effects while being easier to administer to patients.
“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University in Ontario, Canada. “I’m extremely proud of our team, and the extraordinary effort of everyone involved at Anna Biosciences in the furthering of this technology.”
About Anna Biosciences
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to trigger synthetic immunity for COVID-19 and beyond.
Anna Biosciences will continue to develop the Syntem Platform modality for additional therapies for a range of diseases. The company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.
For more information, visit http://annabiosciences.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005353/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azerbaijan Signs its Participation Contract in Expo 2030 Riyadh4.11.2026 08:47:00 CET | Press release
The Republic of Azerbaijan has signed its Participation Contract in Expo 2030 Riyadh. The contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh and H.E. Mr. Anar Alakbarov, Assistant to the President of the Republic of Azerbaijan, during a ceremony held in Baku, Azerbaijan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103050461/en/ The contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh and H.E. Mr. Anar Alakbarov, Assistant to the President of the Republic of Azerbaijan, during a ceremony held in Baku, Azerbaijan. The signing marks an important milestone in Azerbaijan’s participation journey, allowing it to move from planning into delivery of its presence at Expo 2030 Riyadh. Holding the ceremony in Baku reflects the longstanding friendship between the Republic of Azerbaijan and the Kingdom of Saudi Arabia, as well as the importance Azerbaijan attaches to its
GN Corporation’s academic event NCRM NICHE commemorates 21st anniversary of NCRM.4.11.2026 07:10:00 CET | Press release
Kamineni Institute, Hyderabad wins XXI Fujio Cup Quiz on stem cells and regenerative medicine. The XXI edition of Fujio Cup Quiz (FCQ) in NCRM NICHE 2026, hosted by GN Corporation, Japan and Nichi-In centre for Regenerative Medicine (NCRM), was won by Sameer Kumar Reddy and Chava Aravind Kumar from Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India. Ganga Anand Desai and Amith Mathew from Sri Ramachandra Institute of Higher Education and Research, Chennai, India, came runners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103893272/en/ NCRM NICHE is held every year in October since 2006, past 21 years. In 2026, in the active knowledge gaining event, Fujio Cup Quiz, 80 teams from institutes of biotechnology, medicine, veterinary, dentistry and allied health sciences participated, among whom four got to the finals. Kamineni Academy of Medical Sciences, Hyderabad, India won the prestigious Fujio Cup.
Global Consumer Trends 2027: Trust, Transparency and Control Take Centre Stage4.11.2026 06:01:00 CET | Press release
Consumers are no longer placing full trust in brands, technology or the future itself. As uncertainty becomes a permanent feature of daily life, greater value is being placed on reliability, transparency and immediate proof of value. Euromonitor International's Top Global Consumer Trends 2027 report finds consumers seeking greater control as uncertainty reshapes consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103010032/en/ Euromonitor's Top global consumer trends 2027 Drawing on insights from Passport, Euromonitor International's AI-powered market intelligence platform, the report finds consumers looking for balance and control in a world they no longer expect to be certain. Across markets, consumers are placing greater value on reliability, transparency, community and immediate, tangible benefits. “Consumers are no longer simply buying products or services; they're looking for confidence," said Ali Ang
H2SITE Selected for EU Innovation Fund Support to Advance Industrial-Scale Ammonia Cracking in Rotterdam4.11.2026 06:00:00 CET | Press release
The proposed Rotterdam facility would advance the industrial deployment of H2SITE’s hydrogen technology, with a planned production capacity of 20 tons of hydrogen per day. H2SITE has been selected for support from the European Union’s Innovation Fund for the development of an industrial-scale ammonia cracking project in Rotterdam, subject to the formalisation of the grant agreement. The selection marks an important milestone in the company’s work to scale its technology and support the decarbonisation of hard-to-abate industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103379287/en/ Aerial view of the Botlek in Rotterdam. Photo: T.W. van Urk / Shutterstock The project aims to recover and purify hydrogen from imported ammonia close to industrial consumption centres, advancing the industrial deployment of H2SITE’s technology. H2SITE is working closely with industrial stakeholders in Rotterdam to define the project’s
The Estée Lauder Companies Announces Fiscal 2030 Ambition at Its Capital Markets Experience: China Ecosystem Immersion Event4.11.2026 06:00:00 CET | Press release
Sustainable Mid-Single-Digit Organic Net Sales Growth through Fiscal 2030 Adjusted Operating Margin of 16.5%-18.5% in Fiscal 2030Double-Digit Adjusted EPS Growth through Fiscal 2030 The Estée Lauder Companies Inc. (NYSE: EL) today announced its fiscal 2030 ambition at its Capital Markets Experience: China Ecosystem Immersion event in Shanghai, China. Stéphane de La Faverie, President and Chief Executive Officer, and Akhil Shrivastava, Executive Vice President and Chief Financial Officer, outlined the Company’s targets, including its plans to build on the progress of its Beauty Reimagined strategic vision and the execution of its One ELC operating model to deliver sustainable growth while continuing to drive stronger operating leverage and expanded profitability. “We are now entering a new chapter, moving beyond restoring growth to accelerating sustainable, profitable growth and creating long-term value. Our fiscal 2027 outlook reflects this momentum, with accelerating organic sales gro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom